2022
Pathophysiology and management of hypoglycemia in diabetes
Sanchez‐Rangel E, Deajon‐Jackson J, Hwang JJ. Pathophysiology and management of hypoglycemia in diabetes. Annals Of The New York Academy Of Sciences 2022, 1518: 25-46. PMID: 36202764, DOI: 10.1111/nyas.14904.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusCounter-regulatory hormonal responsesMechanism of hypoglycemiaDuration of diabetesManageable chronic diseaseOptimal glycemic controlManagement of hypoglycemiaTreatment of hypoglycemiaNew insulin formulationsDiscovery of insulinGlycemic controlDiabetes mellitusTherapeutic optionsBrain glucoseChronic diseasesNovel therapiesDiabetes managementHypoglycemiaPharmacologic targetHormonal responsesInsulin formulationsDiabetesPatientsCurrent literatureDelivery devices
2019
PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes
Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.Peer-Reviewed Original ResearchConceptsT1DM individualsHealthy controlsDopamine DOutcome measuresAcute C-peptide responseSUVR-1Type 1 diabetes mellitusPET/CT scanningDuration of diabetesMaximal glycemic potentiationC-peptide responseClinical outcome measuresInsulin secretory capacityRoutine clinical measuresD3 receptor densityΒ-cell functionC-peptide releaseQuantitative PET measuresΒ-cell massDynamic PET scansQuantitative outcome measuresAgonist PET radioligandDiabetes mellitusReceptor agonistInsulin antibodies